Telomerase is an almost universal cancer target that consists minimally of a core protein human telomerase reverse transcriptase (hTERT) and a RNA component human telomerase RNA (hTR). Some inhibitors of this enzyme are thought to function by the covalent binding to one or several cysteine residues; however, this inhibition mechanism has never been investigated because of the difficulty in producing telomerase. In this study, we use a recent method to produce recombinant hTERT to analyze the effect of cysteinereactive inhibitors on telomerase. Using mass spectrometry and mutagenesis analysis, we identify several targeted residues in separated domains of the hTERT protein and show that cysteine-reactive reagents abolish the interaction with the CR4/5 region of hTR.
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Telomerase maintains the length of telomeres by catalyzing the elongation of the 3 0 end of telomeric DNA [1] . In humans, the core enzyme is comprised of two components: a catalytic reverse transcriptase protein human telomerase reverse transcriptase (hTERT) and a noncoding RNA human telomerase RNA (hTR) that provides the template for telomere synthesis. hTERT contains four essential domains (TEN, TRBD, RT and CTE), and hTR contains two essential regions required for in vitro activity: the template/pseudoknot (t-PSK) and the CR4/5 domains.
Telomerase is reactivated in 85% of all human tumors and sustains the unlimited proliferation of cancer cells. It is therefore a promising target for cancer treatment. In the past decades, several screening assays have been developed toward the identification of small-molecule inhibitors [2] . Among the compounds described, several of them have been proposed to function by the covalent binding to a cysteine residue [3] [4] [5] [6] [7] . However, this hypothesis has never been confirmed by the direct detection of the adduct on the protein, and the putative position of the targeted residue(s) remains elusive. More interestingly, it has been noticed that telomerase is particularly sensitive to sulfhydryl reagents compared to other enzymes [5] , but the molecular basis of this property is also unknown. Indeed, telomerase does not use cysteines in its catalytic site, and reducing agents are not required for in vitro enzymatic activity [3] . The crossing-points (CP) and E motifs contain well-conserved cysteines, but previous studies have already demonstrated that these residues are not essential for in vitro telomerase Abbreviations DTT, dithiothreitol; EMSA, electrophoretic mobility shift assay; hTERT, human telomerase reverse transcriptase; hTR, human telomerase RNA; MS, mass spectrometry; RC, recovery control; RT-TRAP, real-time telomere repeat amplification protocol; T.A.U., telomerase arbitrary units; t-PSK, template/pseudoknot. activity [8] [9] [10] [11] , leaving no clue to explain the sensitivity of telomerase to this class of drug.
In this study, we use our recent breakthrough method to produce hTERT [12] to identify the targeted residues on the hTERT protein and perform a functional characterization, establishing that multiple regions of hTERT are sensitive to these reagents, including the high-affinity binding region to hTR.
Materials and methods

Production of MBP-hTERT, hTR and telomerase
Recombinant hTERT was produced in Pichia pastoris and purified with a MBP TAG deleted of its periplasmic targeting sequence, as previously described [12] . Western blots were performed after protein purification using the mouse monoclonal anti-MBP antibody (clone R29.6; Merck Millipore, Guyancourt, France). hTR was transcribed in vitro using pT7hTER plasmid (kind gift of J. Lingner, EPFL) or pIDT plasmids containing the t-PSK or CR4/5 (1-209nt or 207-325nt of hTR) under the T7 promoter. Plasmids were linearized using BamHI or EcoRI and purified by phenol/ chloroform followed by ethanol precipitation. About 5 lg of DNA was used as a template in a buffer (40 mM TrisHCl pH 7.9, 8 mM MgCl 2 , 2 mM spermidine, 4 mM NTPs) without DTT and with 250 U of T7 RNA polymerase (New England Biolabs, Evry, France) in a total volume of 100 lL for 3 h at 37°C. The sample was then heated for 2 min at 70°C and stored at À20°C.
For telomerase reconstitution and inhibition experiments, MBP-hTERT (100-300 ngÁlL À1 ) was preincubated 30 min at room temperature with the inhibitor and mixed with an equal amount of hTR for 45 min, then placed at 37°C for 10 min to produce recombinant telomerase typically between 0.3 and 1 lM.
Real-time telomere repeat amplification protocol
Real-time telomere repeat amplification protocol (RT-TRAP) was performed in capillaries using a LightCyclerÒ 2.0 instrument (Roche). Reactions were carried out in a 20 lL scale with LightCyclerÒ FastStart DNA Master SYBR Green I (Roche) with 0.1 lg of telomerase primer TS, 0.05 lg of reverse primer ACX, 0.5 mM additional MgCl 2 and 1 lL of the sample to be tested. Samples were incubated 30 min at 37°C, 10 min at 95°C and amplified in 40 PCR cycles for 60 s at 95°C and 5 s at 60°C. PCR efficiency was calculated by a serial dilution of the most active sample and CP were determined using the second derivative maximum method (LightCyclerÒ software).
For each experiment, the most active sample was arbitrarily set to 100 or 10 000 and values are presented as telomerase arbitrary units (T.A.U.).
Direct telomerase assay
The direct assay was performed as previously described [12] . Unincorporated nucleotides were removed by binding the biotinylated primer to 20 lL of streptavidin-agarose beads (GE Healthcare) for 30 min at room temperature. Beads were washed once with 10 mM Tris-HCl pH 8.0, 1 mM EDTA, 1 M NaCl, and twice with 10 mM Tris--HCl pH 8.0 and 1 mM EDTA. The primer was eluted by heating at 95°C for 10 min in 90% formamide, 10 mM EDTA, 0.5 mM biotin (Sigma) and separated on 20% polyacrylamide-urea sequencing gels (19 : 1 acrylamide : bisacrylamide ratio). The gel was covered with a plastic film, exposed to a phosphorimager screen and scanned using a STORM 860 molecular imager (GE Healthcare).
Cell culture
The ovarian carcinoma cell line A2780 was purchased from ECACC (Salisbury, UK) and the telomerase-negative cell line GM837 was grown in complete RPMI medium supplemented with 10% fetal bovine serum in the presence of penicillin and streptomycin. Cells were cultured 24 h in the presence of Compound A (26 lM), Compound B (4 lM) or Compound C (300 lM), then harvested and resuspended in 1% CHAPS lysis buffer. Telomerase activity was measured by RT-TRAP from an extract of 100 cells. The protein content of the lysate was measured using the BCA assay (Pierce, ThermoFisher Scientific, Waltham, MA, USA) and used to normalize the samples.
Electrophoretic mobility shift assay hTR was synthesized with the addition of 50 lCi of [a-32 P]-CTP and purified by gel filtration using Sephadex G-25 (GE Healthcare). For each lane, 1 lg of MBPhTERT, pretreated 30 min with an inhibitor, was incubated for 1 h with 0.5 lg of labeled hTR in 20 lL. Complexes were migrated at 110 V for 2 h on a 1.5% refrigerated agarose gel in 19 TBE. The gel was fixed for 1 h in 10% acetic acid and 10% ethanol, dried and exposed to a phosphorimager screen. STORM 860 (GE Healthcare) was used to perform the scan and IMAGEQUANT software to quantify the images.
Mutagenesis
Mutants were introduced using QuickChangeXL (Agilent Technologies, Palo Alto, CA, USA) and confirmed by sequencing. The absence of additional mutations in the hTERT coding sequence was checked by sequencing. The hTERT-all29 mutant was produced by gene synthesis (Geneart, Life Technologies, Regensburg, Germany).
Chemical compounds
All compounds, except compound M, were provided by the Institut Curie-CNRS chemical library. Compound M (EZLink Maleimide-PEG2-Biotin; Oda et al. [13] ) was purchased from Thermofisher Scientific (Bremen, Germany, Life Technologies, Regensburg, Germany).
To evaluate the nonspecific reactivity of the compounds, 0.2 unit of the endonuclease BamHI (NEB) was diluted in a 50 lL reaction volume (50 mM Potassium Acetate, 20 mM Tris-acetate, 10 mM Magnesium Acetate, pH 7.9) with each compound and the sample was incubated for 30 min at room temperature. Then, BSA (NEB, 100 lgÁmL À1 final concentration), DTT (1 mM final concentration) and 100 ng of a 6 kb DNA plasmid containing one BamHI site was added and the digestion was performed at 37°C for 2 h. DNA cleavage was monitored on a 0.7% agarose gel.
MALDI time-of-flight mass spectrometry MALDI-TOF mass spectrometry was performed on an AB Sciex 4800 MALDI-TOF/TOF mass spectrometer (AB Sciex, Foster City, CA, USA). Protein and peptide samples were diluted to approximately 1 pmolÁlL À1 , then 0.5 lL of sample was combined with 0.5 lL of a saturated solution of a-cyano-4-hydroxycinnamic acid (Sigma Aldrich) dissolved in 50% acetonitrile in water with 1% formic acid and spotted onto a 384-well AB Sciex MALDI plate (AB Sciex).
Proteomics and mass spectrometry analysis MBP-hTERT in solution digestion was performed using trypsin (1/100, w/w, Sequencing Grade; Promega) for at least 4 h at 37°C in 25 mM ammonium bicarbonate. Peptides were analyzed by nano-LC-MS/MS using an Ultimate 3000 system (Dionex, Villebon sur Yvette, France) coupled to an LTQ-Orbitrap XL mass spectrometer (Thermo Fisher Scientific). Samples were loaded on a C18 precolumn (300 lm inner diameter 9 5 mm; Dionex) at 20 lLÁmin
À1
in 5% acetonitrile and 0.1% TFA. After 3 min of desalting, the precolumn was switched on line with the analytical C18 column (75 lm inner diameter 9 50 cm; C18 PepMap TM , Dionex) equilibrated in Solvent A (2% acetonitrile, 0.1% formic acid). Bound peptides were eluted using different linear gradients of solvent B (80% acetonitrile, 0.085% formic acid) at a 150 nLÁmin À1 flow rate and an oven temperature of 40°C. Data-dependent acquisition was performed on the LTQ-Orbitrap mass spectrometer in the positive ion mode. Survey mass spectrometry (MS) scans were acquired in the Orbitrap on the 475-1200 or 400-1200 m/z range with the resolution set to a value of 60 000. Each scan was recalibrated in real time by coinjecting an internal standard from ambient air into the C-trap ('lock mass option'). The five most intense ions per survey scan were selected for CID fragmentation and the resulting fragments were analyzed in the linear trap (LTQ). Target ions already selected for MS/MS were dynamically excluded for 180 s.
Mass spectrometry data analysis
Data were acquired using the XCALIBUR software (version 2.2; ThermoFisher Scientific) and the resulting spectra were then analyzed via the SEQUEST HT Software (Thermo Fisher Scientific) created with PROTEOME DISCOVERER (version 1.4.0.288; Thermo Scientific) using the SwissProt P. pastoris database, which contains keratins and MBP-hTERT protein sequences.
Maleimide-PEO2-Biotin, A-167 (C 8 H 6 ClNO), A-183 (C 8 H 6 ClNO 2 ) and B-124 (C 6 H 4 OS) alkylation of cysteines, as well as carbamidomethylation of cysteines, oxidation of methionine and protein N-terminal acetylation were set as variable modifications. Specificity of trypsin digestion was set and two missed cleavage sites were allowed. The mass tolerances in MS and MS/MS were set to 10 p.p.m. and 0.6 Da, respectively. The result files were loaded into the myProMS [14] server for further processing. The sequest HT target and decoy search result were validated at 1% FDR with Percolator.
Results
Identification of irreversible inhibitors of telomerase
We have recently developed a new assay that enables to discriminate between inhibitors of telomerase assembly and inhibitors of its catalytic activity. Using this assay, we identified a quinacridine-aminoglycoside derivative, named TAI1, that performs efficient inhibition of telomerase assembly via noncovalent interfacial bonding to both hTR and hTERT [12] . Using the same assay for high throughput screening of the Curie-CNRS chemical library, we now identified new compounds belonging to different chemical classes (Compounds A-E, Fig. 1A and Tables S1-S4). To determine whether these new compounds are reversible or irreversible inhibitors of telomerase, recombinant MBP-hTERT was incubated with each of these compounds, then diluted below the effective concentration of the inhibitor and telomerase was reconstituted in vitro by the addition of hTR. While the dilution of MBP-hTERT before telomerase assembly could revert the inhibition of TAI, this step did not revert the inhibition with this new set of molecules, suggesting that they are irreversible inhibitors targeting hTERT (Fig. 1B) . Of note, a high concentration of reducing agents, such as b-mercaptoethanol or DTT, could completely prevent, but not revert, the action of these inhibitors, while it did not affect the potency of TAI1 (Fig. 1C) . Similar observations have previously been reported for different [4] [5] [6] [7] , or somewhat related [3, 15] telomerase inhibitors, and it has been speculated that these compounds function by binding to one or more unidentified cysteines. This putative mechanism of telomerase inhibition is indeed supported by the observation that maleimide, a well-known compound reacting preferentially with free cysteines at neutral pH, also inhibits telomerase activity in a DTT-sensitive manner (Fig. 1C) . No difference was observed when hTERT was treated before or after assembly with hTR by the compounds (Fig. 1D) . Also, the addition of a primer substrate or dNTP did not protect hTERT from the inhibitory effect of the molecules (Fig. 1E) . Telomerase activity detected by the direct assay showed that Compound A suppressed the DNA polymerase activity of the enzyme (Fig. 1F) .
Cell culture experiments
Compounds were tested in cell culture with the ovarian cancer A2780 cell line and telomerase activity was measured by RT-TRAP at the maximal nontoxic concentration. We could detect a 61% decrease in telomerase activity with Compound A, 21% with Compound B and 22% with Compound C, while Compound D, Compound E and DMSO did not significantly inhibit telomerase (Fig. S1 ).
Structure-activity relationship
Inspection of the chemical structures of the irreversible inhibitors revealed that they all contain an electrophilic moiety (nitrostyrene, halogeno phenyl, conjugated ketone, ester, etc.) susceptible to react covalently with a nucleophilic amino acid (the schemes of the theoretical reactions are presented in Fig. S2 ). Benefiting from the diversity of our chemical library, we searched for analogues of Compounds A-E in the aim to perform structure-activity relationship analysis and to identify more potent compounds. For the series corresponding to Compound B (nitrostyrenes, Table S1 ), Compound C (conjugated ketones and esters, Tables S2 and S3) and Compound  D (thiadiazolones, Table S4 ), the in vitro potency against telomerase was poorly affected by slight variations in chemical structures (Tables S1-S4 ), thereby strongly suggesting that these compound series are nonspecific reagents. On the contrary, we observed a striking and coherent structure-activity relationship in a series of flavonoid compounds derived from Compound A. Indeed, even slight modifications of the scaffold led to a strong decrease in activity (Fig. S3) . Such strong variation in potency between closely related compounds could be due to differences in intrinsic properties (solubility and aggregation) or might result from modulation of inductive effects that modify their reactivity [16] . As hydroxyl groups of these flavonoid derivatives are methylated, the redox cycling mechanism previously described in PAINS is prevented. Nevertheless, these compounds are still predictably reactive through their common electrophilic region. Therefore, an alternative explanation to the structure-activity observed could be a specific docking of the Compound A scaffold on hTERT with very well-defined interactions that would favor a covalent reaction with a specific cysteine. To decipher between these possibilities, this set of flavonoid derivatives was tested on the restriction endonuclease BamHI, which is known to be sensitive to sulfhydryl reagents [17] . A similar trend in structure-activity relationship was found, suggesting that the higher potency of Compound A and some of its analogues comes from their physical properties (solubility, chemical reactivity, etc.; Fig. S3 ).
Mass spectrometry identification of the targeted residues
In order to identify the targeted residues on hTERT, a flavonoid derivative (Compound A), a nitrostyrene derivative (Compound B) and maleimide-PEG2-biotin (Compound M) were selected in order to identify the mechanism of telomerase inhibition. hTERT was separately treated by three different compounds at a concentration inhibiting 70-90% of telomerase activity, and the protein was analyzed by a proteomic approach. Out of the 29 cysteines present in hTERT, 26 were covered during our LC-MS/MS analysis (Table S5) , and two adducts were reproducibly identified on two cysteines of the TRBD: C426 and C528. Six other positions were also seldom found to be alkylated: C199, C271, C740, C814, C896 and C1043 ( Fig. 2A and Fig. S4 ). Other products were not detected in every experiment and were not seen with all the compounds, reflecting either a lower level of alkylation for these residues or a more difficult detection of some peptide adducts. We generated single as well as a double mutant for the two main cysteines (C426A and C528A). Surprisingly, these mutants displayed wildtype activity and no detectable resistance to the compounds, suggesting that other residues are the targets of these molecules leading to irreversible inhibition.
In order to increase the sensitivity of our detection, we treated hTERT with a high concentration of reagent producing > 99.99% telomerase inhibition. We could now observe a full alkylation of the cysteine 528 of the TRBD and also a full alkylation of the cysteine 896, located in the motif D of the RT domain. We therefore generated a mutant for the three main sites identified (C426A, C528A and C896A). This triple mutant displayed wild-type activity and a similar sensitivity to all three compounds (Fig. 2B) , therefore at least another critical position is implicated in the effect of these inhibitors.
Noticeably, even in these experiments performed with an excess of reagent, no adduct could be detected on an amino acid other than a cysteine. This was surprising because electrophilic molecules, such as maleimide and iodoacetamide can react, although at a lower rate, with other amino acids such as histidines and lysines [18] . In order to investigate the reactivity with other amino acids, an angiotensin peptide (DRVYIHPFHL) containing no cysteine was incubated with the compounds. After a treatment with iodoacetamide, adducts were detected at positions 1, 6 and 9 by MALDI-MS/MS and LC-MS, suggesting a reactivity with the N-terminal amine group and with the imidazole ring of histidines. We also detected the presence of adducts at positions 1 and 6 with maleimide-PEG2-biotin and Compounds A and B by MALDI-MS/MS (Fig. S5) , but attempts to detect these peptide adducts by LC-MS/MS were unsuccessful. Therefore, our analysis does not allow us to exclude the possibility that some undetected alkylation occurred on non-cysteine residues within the hTERT protein.
Mutagenesis of all hTERT cysteines
As cysteines are the main target of electrophilic reagents in proteins, we decided to evaluate the functional importance of the cysteine residues in the hTERT protein. Each cysteine was independently mutated to alanine. A total of 29 single mutants were produced and tested for telomerase activity. All mutant proteins were expressed close to normal level, except the C468A, which was reproducibly recovered at a lower level (Fig. 3A) . Three mutants (C156A, C166A and C171A) corresponding to residues present in the most conserved part of the TEN domain displayed a decreased telomerase activity (Fig. 3B) . Two of them were covered during our MS analysis and were never found to be alkylated. The weakest mutant displayed at least 10-20% telomerase activity, and was not as severely defective as hTERT treated by our compounds. This suggests that telomerase inhibition by this class of reagent may not be caused by the neutralization of an essential cysteine of hTERT.
In order to identify the main inhibitory adduct, we tested each of the 29 mutants for resistance against Compound A. Surprisingly, all the inhibition curves were pretty similar (Fig. 4A) , within the twofold variation we observed when using telomerase reconstituted from different protein preparations. This demonstrates that the sensitivity of telomerase to sulfhydryl reagents is not due to a unique cysteine. To further test the absence of a preferential site, we produced two hTERT fragments separately, containing the TEN-TRBD and RT-CTE domains, respectively (Fig. 4B) . Each fragment is inactive when mixed in vitro with hTR, but both fragments reconstitute detectable telomerase activity when combined together with hTR (Fig. 4C) . To test if a preferential reacting site exists in hTERT, the TEN-TRBD and RT-CTE fragments were incubated separately with different concentrations of Compounds A or M, then the reagent was inactivated using 10 mM DTT, and telomerase activity was reconstituted by the addition of the complementary nontreated TERT protein fragment and with hTR. The inhibition curves were again very similar in all conditions (Fig. 4D) , demonstrating the existence of at least one critical residue in each fragment.
In order to bypass the redundancy between the multiple cysteines, we synthesized a hTERT gene with all 29 cysteines mutated together to alanines (hTERTall29), so as to exclude first the implication of noncysteine residues, and then reintroduce each cysteine one by one and test their role independently. However, the yeast expressing this multimutant grew very slowly, suggesting a toxicity caused by a defective folding of the protein. hTERT was recovered at a 20-fold lower yield than the wild-type, with more degradation products, and did not reconstitute any detectable telomerase activity (Fig. 4B,C) . 
Sulfhydryl reagents prevent the interaction with the CR4-5
In order to characterize the functional consequence of the alkylation, we monitored the binding ability of wildtype hTERT to hTR. At high reagent concentration, hTERT displayed a reduced binding to hTR. This was due to a specific loss of affinity for the CR4/5 region, while the binding to the t-PSK region was not affected (Fig. 5A) . A similar effect was observed with Compound B or maleimide, in a DTT-sensitive manner. On the contrary, hTERT oxidation by a pyrogallol derivative reduced both the t-PSK and the CR4-5 interaction (Fig. S6) . The CR4/5 region is the high-affinity binding site of hTR for hTERT, whereas the t-PSK region provides only a lower interaction [19] . The ability of cysteine-reactive compounds to disrupt the high-affinity binding site without affecting the lower binding site demonstrates a particular sensitivity of the CR4-5 binding interface of hTERT to this class of drug.
By preventing the association between hTERT and hTR, sulfhydryl reagents can act as telomerase assembly inhibitors. However, the binding of hTR did not protect hTERT from the inhibitory effect of the compounds on telomerase activity (Fig. 1D) . This is consistent with the existence of a redundant sensitivity in the RT-CTE domains of hTERT (Fig. 4D) , which are not involved in high-affinity binding with hTR. This suggests that sulfhydryl reagents can target telomerase both at the preassembly and postassembly stages. Noticeably, the specific reduction in the binding to the CR4-5 required a fivefold higher concentration of reagent than the one required to inhibit telomerase activity. This is again consistent with the existence of multiple redundant sites of alkylation, and suggests that each hTERT molecule can already be catalytically inactivated by at least one random alkylation at a concentration where only a fraction of the hTERT population was alkylated on the critical residue(s) implicated in the CR4-5 affinity.
Lysine 511 is implicated in the loss of CR4/5 affinity hTERT was treated with Compound A before or after assembly with the CR4-5 RNA fragment and was subjected to electrophoretic mobility shift assay (EMSA) analysis. The reagent suppressed the proteinÁRNA association less efficiently on an already assembled complex, suggesting that some alkylation occurs in the CR4-5 binding interface (Fig. 5B) . C528 is the only cysteine present in the CR4-5 binding interface and it was found to be alkylated in every one of our MS experiments. However, we observed that the C528A mutant still loses its affinity for the CR4-5 as efficiently as wild-type hTERT when treated with Compound A or maleimide (Fig. 5C) . Similar results were observed with the double mutant for the two recurrently alkylated cysteines of the TRBD (C528A C426A). This suggests the implication of a noncysteine residue. While searching for alternative targets, we noticed that the peptide 503-511 (K.LSLQELTWK.M) was no longer detected in the LC-MS/MS experiments performed with a high concentration of reagents. The alkylation of K511 should induce a miss-cleavage by trypsin and prevent the detection of the alkylated peptide. In order to test the role of Lysine 511, we generated a single (K511A) and a triple (K511A, C426A and C528A) mutant, and tested them for CR4/5 binding after treatment by Compound A. Although the single mutant behaved similarly to the wild-type, the triple mutant displayed a significant resistance to the drug, strongly suggesting that K511 is indeed alkylated and implicated in the loss of CR4/5 affinity (Fig. 5C,D) . This triple mutant displayed wild-type level of telomerase activity. Therefore, none of the identified residues are essential and the loss of affinity for the CR4-5 is due to a steric blockage mediated by adducts. The localization of K511 and C528 predicted from an alignment of human TERT with Oryzias latipes TERT shows that both alkylated positions are contiguous to critical amino acids (W477 and F496), previously described to be implicated in the binding to the P6.1 helix in one available structure [20] (Fig. 6 ). This explains how adducts at these positions can suppress the affinity of hTERT for the CR4/5 region.
Discussion
In this study, we have shown that the nonspecific covalent binding of electrophilic reagents to hTERT can inhibit telomerase activity through at least two different mechanisms. The alkylation of the CR4-5 binding interface in the TRBD domain prevents telomerase assembly, while an already assembled telomerase is also catalytically inactivated because of sensitive residues present in the RT-CTE domain. This high number of targets differs from the profile reported for the reverse transcriptase (RT) of the moloney murine leukemia virus and of the avian myeloblastosis virus, whose sensitivity to sulfhydryl reagent is mainly due to a residue present in the primer-binding domain, and is completely blocked after the addition of the primer substrate [21, 22] .
Telomerase could be a major drug target for cancers, and our work confirms that it can be targeted by sulfhydryl reagents. The development of irreversible inhibitors targeting noncatalytic cysteine residues has recently proved to be successful in the clinic in the case of afatinib, an ErbB kinase inhibitor. This drug was designed by associating a mild electrophile to a highaffinity compound that specifically targets the reactivity to a cysteine of the ATP binding pocket [23] . The present study suggests that several independent telomerase inhibitors can be developed following the same strategy for the alkylable residues as that we have identified on hTERT. In particular, Cys528 and Lys511 are exposed in the CR4-5 binding interface before assembly with hTR [24] , while Cys896 is positioned at the entry of the dNTP binding pocket and could thus be used to lock a competitive inhibitor. The main effort now remains to identify such scaffolds that dock with high affinity close to these positions and can direct the alkylation process toward one of these residues.
Indeed, all the irreversible inhibitors identified through our screening assay showed either poor structure-activity relationships or a similar trend with the restriction enzyme BamHI. This strongly suggests that these compounds are not selective telomerase inhibitors, but most probably nonspecific alkylating reagents. The identification of several alkylated cysteines on the hTERT protein treated with these compounds strengthened this conclusion. These observations therefore remind that a low IC 50 and even strong structure-activity relationship do not always mean specificity. Previously, several cysteine-reactive molecules have been described as specific telomerase inhibitors on the basis that they do not inhibit a panel of other polymerases, including HIV RT or TAQ DNA polymerase [3, 4, 14, 25] . However, HIV RT is widely known to be completely resistant to millimolar concentration of maleimide [21, 26, 27] and that all its cysteines are dispensable for its RNA-dependent DNA polymerase activity [28] , while TAQ DNA polymerase does not contain any cysteine in its protein sequence, and is highly resistant to all our compounds (data not shown). Therefore, in comparative experiments between several polymerases, the selectivity of the inhibitor may only be apparent, reflecting high differences in sensitivity between different enzymes. Indeed, telomerase has been pointed to be among the most N-ethylmaleimide-sensitive enzymes reported in the literature [5] . Therefore, previous studies may have just observed the particular sensitivity of telomerase to non-specific sulfhydryl reagents rather than having discovered a truly selective inhibitor, resulting from a specific molecular recognition.
After a survey of the patented or published molecules described as telomerase inhibitors, we anticipate that a significant proportion of them may prove to act via the mechanism investigated in the present study. Indeed, the chemical structure of alterperylenol [25] , curcumin or TNQX [29] clearly suggests possible reactions with thiols, while nitrostryrene derivatives similar to our Compound B were and are still considered as mixed-type noncompetitive inhibitors of telomerase [2, 3, 15] , whereas our data establish that these molecules are first of all covalent reagents. As reducing agents, such as b-mercaptoethanol or DTT, readily inactivate most common electrophilic reagents, we strongly recommend to test any new telomerase inhibitor with or without a pretreatment with an excess of such reducing agents to explore the possibility that the inhibitor (or a byproduct) is reacting to hTERT. Indeed, unexpected protein reactivity is the most common artifact encountered during drug screening [30, 31] , and was sometimes only detected in late drug development [32] . Given the very high sensitivity of telomerase to such reagents, stringent controls must be particularly reinforced in this case. In the course of this study, we have noticed important pitfalls in the characterization of telomerase inhibitors, and can now suggest some recommendations for the identification of specific irreversible inhibitors. From the current TERT structures, cysteines appear to be well separated in hTERT; therefore, a specific small-molecule inhibitor should target a single well-defined residue. As we have demonstrated that each cysteine-to-alanine mutant of hTERT displays a significant level of telomerase activity, a specific inhibitor could be identified by showing the resistance of one of these single mutants to the drug. Finally, a specific telomerase covalent inhibitor would not be expected to react with the restriction endonuclease BamHI; therefore, the BamHI assays described here provides a simple and sensitive way to eliminate cysteine-reactive compounds with poor selectivity. Together, these observations should help distinguishing truly potent telomerase inhibitors from unspecific reagents alkylating any free cysteine.
Finally, even if none of our compounds was really selective, we noticed that some of them could decrease telomerase activity in cancer cells cultured in vitro. As in previous studies [5] [6] [7] , this was associated with a rapid cellular toxicity that is most probably not related to telomerase inhibition, as a comparable toxicity was observed on telomerase-negative cell lines. In conclusion, our analysis supports the view that cysteine-reactive molecules are a promising class of drug to efficiently inhibit telomerase, but highly specific inhibitors need to be developed to be able to target this enzyme by these class of reagents in humans. 
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